Atherosclerotic plaque inflammation: the final frontier?
Aikawa
Masanori
M
Donald W Reynolds Cardiovascular Clinical Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. maikawa@rics.bwh.harvard.edu
Libby
Peter
P
D000818:Animals; D001161:Arteriosclerosis / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D015415:Biomarkers / Q000032:analysis; D002097:C-Reactive Protein / Q000032:analysis / Q000502:physiology; D019013:CD40 Antigens / Q000502:physiology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007249:Inflammation / Q000378:metabolism / Q000503:physiopathology; D008264:Macrophages / Q000378:metabolism / Q000502:physiology; D018384:Oxidative Stress; D017382:Reactive Oxygen Species / Q000378:metabolism; D013927:Thrombosis / Q000503:physiopathology
D015415:Biomarkers; D019013:CD40 Antigens; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017382:Reactive Oxygen Species; D002097:C-Reactive Protein